Crosspoint Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $3.6M

  • Investors
  • 11

Crosspoint Therapeutics General Information

Description

Developer of a stealth-body technology designed to reduce off-target toxicity in antibody therapies. The company's platform applies proprietary Fc-silencing mutations that markedly diminish Fc-effector functions, demonstrates no meaningful binding or activity across Fc gamma receptors, supports incorporation of these modifications into diverse antibody backbones, and is used to advance internal and partnered drug discovery programs, enabling biopharmaceutical developers and research organizations to generate next-generation antibody therapeutics with improved safety profiles, more controlled pharmacologic activity, and broader applicability for refractory diseases with high unmet clinical demand.

Contact Information

Website
www.crosspointrx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1306 593-8 Dongtangiheung-ro
  • Hwaseong, Gyeonggi 18469
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Drug Delivery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1306 593-8 Dongtangiheung-ro
  • Hwaseong, Gyeonggi 18469
  • South Korea
+82

Crosspoint Therapeutics Timeline

2023202420252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Crosspoint Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 05-Mar-2026 $3.6M Completed Pre-Clinical Trials
4. Early Stage VC 04-Mar-2026 Completed Generating Revenue
3. Accelerator/Incubator 08-May-2024 Completed Pre-Clinical Trials
2. Seed Round 01-Apr-2024 $1.58M $1.58M Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2023 Completed Startup
To view Crosspoint Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Crosspoint Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a stealth-body technology designed to reduce off-target toxicity in antibody therapies. The company's platf
Biotechnology
Hwaseong, South Korea
7 As of 2026

Valby, Denmark
 

Suzhou, China
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Crosspoint Therapeutics Competitors (3)

One of Crosspoint Therapeutics’s 3 competitors is Genmab, a Formerly VC-backed company based in Valby, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genmab Formerly VC-backed Valby, Denmark
Alphamab Private Equity-Backed Suzhou, China
Duality (Biotechnology) Venture Capital-Backed London, United Kingdom
You’re viewing 3 of 3 competitors. Get the full list »

Crosspoint Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Crosspoint Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
KUDOS Company Investment Bank Minority
BMI Korea Corporation Minority
Soo Investment Capital Venture Capital Minority
YBiologics Corporation Minority
Tech Incubator Program for Startup Accelerator/Incubator
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

Crosspoint Therapeutics FAQs

  • When was Crosspoint Therapeutics founded?

    Crosspoint Therapeutics was founded in 2022.

  • Where is Crosspoint Therapeutics headquartered?

    Crosspoint Therapeutics is headquartered in Hwaseong, South Korea.

  • What is the size of Crosspoint Therapeutics?

    Crosspoint Therapeutics has 7 total employees.

  • What industry is Crosspoint Therapeutics in?

    Crosspoint Therapeutics’s primary industry is Biotechnology.

  • Is Crosspoint Therapeutics a private or public company?

    Crosspoint Therapeutics is a Private company.

  • What is Crosspoint Therapeutics’s current revenue?

    The current revenue for Crosspoint Therapeutics is .

  • How much funding has Crosspoint Therapeutics raised over time?

    Crosspoint Therapeutics has raised $7.66M.

  • Who are Crosspoint Therapeutics’s investors?

    KUDOS Company, BMI Korea, Soo Investment Capital, YBiologics, and Tech Incubator Program for Startup are 5 of 11 investors who have invested in Crosspoint Therapeutics.

  • Who are Crosspoint Therapeutics’s competitors?

    Genmab, Alphamab, and Duality (Biotechnology) are competitors of Crosspoint Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process